title: Levonorgestrel Intrauterine Device Use in Overweight and Obese Women.
abstract: The levonorgestrel intrauterine device (LNG-IUD) is a safe, effective, long-acting, reversible contraceptive that reduces unintended pregnancy and decreases heavy menstrual bleeding. Many procedures such as IUD insertion are more challenging in overweight and obese women. The objective of this study was to describe LNG-IUD insertion, continuation, and complications in overweight and obese women in an ethnically diverse population in Hawai'i. A retrospective cohort study of women who had a LNG-IUD inserted at the University of Hawai'i, Department of Obstetrics and Gynecology Resident and Faculty practice sites between January 2009 and December 2010 was performed. A total of 149 women were followed. The most commonly reported races were Asian (32%), Native Hawaiian (26%), and non-Hawaiian Pacific Islander (20%). The mean BMI of the study population was 28.4 (standard deviation 7.2) with 37% classified as normal weight, 30% as overweight, and 33% as obese. Overall, 76% of women continued the LNG-IUD 12 months after insertion. No statistically significant difference emerged in 12-month IUD continuation between the BMI groups. Difficult (5%) and failed (3%) IUD insertions were rare for all BMI groups. IUD complications occurred in 9% of women and included expulsion and self-removal. In this diverse population, the majority of women continued to use the LNG-IUD one year after insertion with low rates of difficult insertions and complications.
authors.affiliation: Department of Obstetrics & Gynecology, John A. Burns School of Medicine, University of Hawai'i; Honolulu, HI.
authors.forename: Lynne Y
authors.initials: LY
authors.lastname: Saito-Tom
authors.affiliation: Department of Obstetrics & Gynecology, John A. Burns School of Medicine, University of Hawai'i; Honolulu, HI.
authors.forename: Reni A
authors.initials: RA
authors.lastname: Soon
authors.affiliation: Department of Obstetrics & Gynecology, John A. Burns School of Medicine, University of Hawai'i; Honolulu, HI.
authors.forename: Sara C
authors.initials: SC
authors.lastname: Harris
authors.affiliation: Department of Obstetrics & Gynecology, John A. Burns School of Medicine, University of Hawai'i; Honolulu, HI.
authors.forename: Jennifer
authors.initials: J
authors.lastname: Salcedo
authors.affiliation: Department of Obstetrics & Gynecology, John A. Burns School of Medicine, University of Hawai'i; Honolulu, HI.
authors.forename: Bliss E
authors.initials: BE
authors.lastname: Kaneshiro
mesh_terms: D000328:Adult; D003267:Contraception / Q000706:statistics & numerical data*; D003271:Contraceptive Agents, Female / Q000627:therapeutic use*; D005260:Female; D006254:Hawaii / Q000208:ethnology; D006801:Humans; D007436:Intrauterine Devices, Medicated / Q000706:statistics & numerical data*; D016912:Levonorgestrel / Q000627:therapeutic use*; D008297:Male; D009765:Obesity / Q000208:ethnology; D050177:Overweight / Q000208:ethnology*; D012189:Retrospective Studies; D055815:Young Adult
chemical_list: D003271:Contraceptive Agents, Female; D016912:Levonorgestrel